The goal of this study was to determine whether clozapine is a cost-effective treatment for treatment-resistant schizophrenia.
Data were collected on 96 treatment-resistant patients with schizophrenia for 2 years before they entered a clozapine treatment study and for at least 2 years after they entered the study.
Information about the cost of inpatient and outpatient treatment, housing costs, other costs, and family burden through direct interview or questionnaire of these patients and their families were available for 47 of the 96 patients.
Data on lost income and Social Security disability insurance were also obtained.
Ontcome measures included psychopathology, finality of life, global functioning, work function, and rehospitalization.
Mots-clés Pascal : Schizophrénie, Psychose, Neuroleptique, Clozapine, Psychotrope, Chimiothérapie, Traitement, Analyse coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Système santé, Homme
Mots-clés Pascal anglais : Schizophrenia, Psychosis, Neuroleptic, Psychotropic, Chemotherapy, Treatment, Cost analysis, Health economy, United States, North America, America, Health system, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0038292
Code Inist : 002B02B03. Création : 199406.